Inside a record quarter for new cancer treatments

Introduction: a report that never makes headlines, yet changes lives

Fifteen new approvals in three months

On July 2, 2026, the American Association for Cancer Research published its quarterly report on FDA oncology approvals for the period from April to June 2026. The figure is striking: at least fifteen new treatments or new indications were approved in three months, covering breast cancer, bladder, prostate, blood cancers, and several rare cancers.

This isn't the kind of news that dominates headlines. Yet behind every line of this technical report lies a concrete reality: patients who, today, have access to therapeutic options that simply didn't exist six months ago.

Why this report deserves a full feature

I chose to dwell on this document, often reserved for specialists, because it illustrates with rare precision the real acceleration of Western oncology research. I'll walk you through the most notable approvals, without ever turning the legitimate hope they inspire into a promise of miracles.

Breast cancer alone received five new approvals this quarter, a figure that reflects the scale of research concentrated on this disease, which will affect, according to projections cited by the AACR, nearly 322,000 women in the United States this year.

Breast cancer, this quarter's biggest winner

Vepdegestrant, a world first

Among the most significant approvals is vepdegestrant, marketed as Veppanu, for metastatic ER-positive, HER2-negative breast cancer carrying an ESR1 mutation. It is the first PROTAC ever approved by the FDA for cancer, an entirely new class of drugs that degrades the estrogen receptor through a mechanism different from classic hormonal treatments.

Clinical data presented at the SABCS 2025 conference show that patients carrying the ESR1 mutation treated with vepdegestrant experienced significantly longer progression-free survival than those treated with fulvestrant, the reference treatment until now.

Sacituzumab govitecan, new hope for triple-negative cancer

Sacituzumab govitecan, known by the brand name Trodelvy, also received an expanded approval for metastatic triple-negative breast cancer, in patients not eligible for immunotherapy targeting PD-1 or PD-L1. This drug, which targets the TROP2 protein, is now approved as an alternative to first-line chemotherapy, and can also be combined with pembrolizumab for patients whose tumor expresses PD-L1.

Triple-negative breast cancer, historically one of the hardest to treat due to the absence of classic molecular targets, thus gains an additional option that could change the clinical trajectory for many patients.

Datopotamab deruxtecan and the expansion of ADCs

A new targeted option for patients ineligible for immunotherapy

Datopotamab deruxtecan, or Datroway, was also approved this quarter for metastatic triple-negative breast cancer in patients unable to receive an immune checkpoint inhibitor. Like sacituzumab govitecan, it targets the TROP2 protein, illustrating an underlying trend toward antibody-drug conjugates, a rapidly expanding therapeutic class.

This approval offers a direct alternative to conventional chemotherapy for a subgroup of patients who, until now, had very few targeted options, a development worth highlighting without claiming it to be a universal cure.

Trastuzumab deruxtecan extends its reach to earlier stages

Trastuzumab deruxtecan, already approved for HER2-positive or HER2-low metastatic breast cancers, received two new indications this quarter: as neoadjuvant treatment before surgery for stage 2 or 3 cancers, and as adjuvant treatment for patients with residual disease after standard neoadjuvant treatment.

This expansion into earlier stages of the disease represents a paradigm shift: a drug initially reserved for advanced forms of cancer now finds its place at the earliest lines of treatment, potentially before the disease even progresses.

Advances in bladder cancer

Durvalumab changes the game for high-risk forms

In the field of bladder cancer, durvalumab, or Imfinzi, was approved in combination with BCG for high-risk non-muscle-invasive forms of bladder cancer, in patients who have not yet received BCG treatment. Before this approval, immunotherapy was generally only accessible after BCG treatment failure.

This approval therefore allows patients to receive immunotherapy right from the start, rather than waiting for prior treatment failure, which could significantly improve long-term outcomes for this patient population.

Atezolizumab and a world first on circulating tumor DNA

Even more notable, atezolizumab, marketed as Tecentriq, was approved as adjuvant treatment for muscle-invasive bladder cancer in patients with circulating tumor DNA after cystectomy, signaling molecular residual disease. According to the AACR, this is the first FDA approval for a solid tumor that includes a circulating tumor DNA positivity requirement.

This approval marks an important methodological turning point: the decision to treat no longer relies solely on imaging or classic clinical markers, but on a precise molecular signature detected in the patient's blood.

Prostate cancer faces new combinations

Capivasertib targets a precise molecular weakness

Prostate cancer, which will affect roughly one in eight men in the United States during their lifetime according to statistics cited by the AACR, also gains new options. Capivasertib, or Truqap, was approved in combination with abiraterone and prednisone for metastatic prostate cancers with a PTEN gene deficiency.

Capivasertib acts as an AKT inhibitor, a protein whose activity remains abnormally elevated in PTEN-deficient cancers, fueling tumor progression. This approval therefore directly targets a precise molecular mechanism rather than attacking the disease broadly.

A development affecting a significant minority of patients

According to the AACR, nearly 10% of prostate cancer cases are diagnosed after the disease has already metastasized, a patient subgroup for whom targeted therapeutic options like capivasertib can make a significant difference in long-term disease management.

This approval illustrates a broader trend in oncology: rather than seeking a universal treatment, research is identifying precise molecular subgroups to offer them tailored therapeutic combinations.

Rare cancers, often overlooked by the public

Zenocutuzumab for a rare genetic mutation

Zenocutuzumab, or Bizengri, was approved for advanced cholangiocarcinoma carrying an NRG1 gene fusion, an extremely rare subtype of bile duct cancer. This bispecific antibody simultaneously targets the HER2 and HER3 proteins, blocking the formation of a molecular complex that fuels tumor growth.

For patients carrying this rare genetic fusion, this approval offers a second line of treatment where options were previously extremely limited, illustrating the importance of research on cancer subtypes that statistically affect very few patients, but whose lives matter just as much.

Pivekimab sunirine against a rare, aggressive leukemia

Pivekimab sunirine, or Decnupaz, was approved to treat blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive form of blood cancer. This antibody-drug conjugate targets the CD123 protein, universally expressed by this disease's cells, to deliver an agent capable of directly damaging cellular DNA.

These approvals for rare cancers never generate as much media attention as treatments for the most common cancers, but they often represent the only glimmer of hope for patients whose disease is too rare to attract massive pharmaceutical investment.

Innovations in cell therapy and hematology

Afamitresgene autoleucel, a first traditional approval

Afamitresgene autoleucel, marketed as Tecelra, moved from an accelerated approval obtained in 2024 to full traditional approval this quarter, with an expanded indication now including pediatric patients aged 12 and older with metastatic synovial sarcoma. It is the first T-cell receptor-engineered T-cell therapy ever approved, and the first cell therapy immunotherapy for synovial sarcoma.

This conversion from accelerated to traditional approval is significant in itself: it means longer-term follow-up data confirmed the clinical benefit initially observed, an important milestone in the regulatory journey of any new treatment.

Sonrotoclax, a new generation of BCL-2 inhibitors

Sonrotoclax, or Beqalzi, received accelerated approval for mantle cell lymphoma refractory or relapsed after at least two prior lines of treatment including a BTK inhibitor. It is a second-generation BCL-2 inhibitor, designed to overcome the limitations of venetoclax, the first-generation reference treatment in this class.

For patients whose lymphoma has resisted several prior lines of treatment, this new generation of inhibitors represents an additional option at a point when therapeutic alternatives are becoming increasingly scarce.

A quiet revolution for older patients

Decitabine-cedazuridine, a treatment taken at home

For acute myeloid leukemia in patients aged 75 and older or ineligible for intensive induction chemotherapy, the combination of decitabine and cedazuridine, marketed as Inqovi, was approved in combination with venetoclax. These oral tablets allow patients to receive their treatment at home, rather than making repeated trips for infusions.

This seemingly logistical detail carries considerable human weight for older patients who are often frail, for whom every trip to an infusion center represents significant physical and logistical effort.

A new approach for stem cell transplants

An allogeneic immune therapy based on regulatory T cells, marketed as Tregzi, was approved for patients with hematologic cancers undergoing a stem cell transplant. It is the first approved immunotherapy to use regulatory T cells, designed to help cells recover after transplant conditioning and reduce the risk of chronic graft-versus-host disease.

This approval, less publicized than others, could nonetheless significantly reduce one of the most feared complications of stem cell transplants, an advance whose clinical impact deserves close monitoring in the years ahead.

What this pace of approvals reveals about Western research

An acceleration owing nothing to chance

This pace of fifteen approvals in a single quarter is no accident. It reflects decades of sustained investment in basic and clinical oncology research, largely concentrated in major North American and European research centers, as well as close cooperation between pharmaceutical companies and academic institutions.

This acceleration also illustrates the growing efficiency of FDA regulatory processes, which have developed accelerated approval pathways that make promising treatments for serious or rare diseases available to patients more quickly, while maintaining rigorous follow-up requirements.

A model inspiring other regions of the world

This American regulatory model, combining scientific rigor with speed of execution, is increasingly inspiring regulatory agencies elsewhere in the Western world, which are seeking to shorten access times to innovative treatments without compromising patient safety.

This positive dynamic contrasts with the difficulties in accessing innovative treatments still observed in several regions of the world less well equipped with research infrastructure and robust regulatory capacity.

The limits worth keeping in mind

Access and cost, persistent challenges

It would be dishonest to celebrate this report without mentioning the access and cost issues that often accompany these new treatments. The targeted therapies, antibody-drug conjugates, and cell therapies mentioned in this report generally rank among the most expensive oncology treatments, raising legitimate questions about equity of access among patients depending on their insurance coverage or country of residence.

These economic issues aren't addressed in detail in the AACR report, but they inevitably accompany every new approval, and deserve to be kept in mind by any reader following this kind of news with unqualified enthusiasm.

The time needed to measure long-term benefits

Several of these approvals, notably those obtained under accelerated approval status, remain subject to long-term follow-up requirements before their full clinical benefit is completely confirmed. This ongoing validation process, though less spectacular than an initial approval announcement, remains essential to guarantee the real safety and effectiveness of these treatments over the long term.

I therefore choose to present this report with the enthusiasm it deserves, while reminding readers that medicine advances through successive validations, rarely through immediate and definitive certainties.

The role of patients in this scientific acceleration

Clinical trials that depend on voluntary participation

Each of these fifteen approvals rests on the participation of thousands of volunteer patients in clinical trials, often over several years, before the data is judged solid enough to justify regulatory approval. This contribution, rarely highlighted in media coverage of these announcements, deserves explicit recognition.

Without this participation, none of the data presented at conferences like SABCS 2025 or the AACR-NCI-EORTC conference on molecular targets would exist, and this quarterly report would remain empty of any concrete content.

A reminder for patients currently in treatment

For patients currently undergoing cancer treatment, this report should serve as a reminder that open dialogue with their oncology team remains essential to assess whether one of these new approvals might apply to their specific clinical situation, based on their tumor subtype and molecular profile.

No popular science article, however thorough, replaces an individualized medical evaluation, a principle I deliberately repeat in every one of my texts about medical advances.

What this means for the future of oncology research

Toward ever more personalized medicine

The trend that clearly emerges from this quarterly report is one of increasingly personalized oncology medicine, structured around precise molecular signatures like ESR1 mutations, PTEN deficiencies, or NRG1 gene fusions, rather than broad, generic cancer categories.

This approach, though more complex to implement diagnostically, allows more precise targeting of patients likely to genuinely benefit from a given treatment, potentially reducing unnecessary side effects in patients for whom the treatment would not be effective.

The next frontier: integrating blood biomarkers

The approval of atezolizumab based on the detection of circulating tumor DNA may be just the beginning of a broader trend toward the systematic integration of blood biomarkers into oncology treatment decisions, an evolution that could transform how clinicians monitor recurrence and adjust treatments in real time.

This technological frontier, still in its early stages, could redefine in the coming years how the entire Western health system approaches post-treatment monitoring of cancer patients.

A reminder about overall cancer statistics

Figures that put these advances in context

The AACR report notes that breast cancer will show a five-year relative survival rate above 90% in recent years, a figure that, while encouraging, should never obscure the difficult reality faced by patients whose disease doesn't respond to standard treatments, particularly those with triple-negative or metastatic forms.

These encouraging statistics, combined with this quarter's fifteen new approvals, paint an overall positive trajectory for breast cancer research, without erasing the challenges that persist for the hardest-to-treat patient subgroups.

Prostate cancer, a screening challenge as much as a treatment one

For prostate cancer, the fact that nearly 10% of cases are diagnosed after metastasis highlights a challenge that goes beyond treatment alone: early screening, which remains uneven across populations and health systems, even in the most medically advanced Western countries.

New therapeutic combinations like capivasertib offer real hope for late-diagnosed patients, but they do not replace the crucial importance of early and regular screening for the entire at-risk male population.

Research funding, the blind spot of public debate

Federal budgets that make this pace possible

Behind every FDA approval lies funding that's often invisible to the public: grants from the National Institutes of Health, private investment from major pharmaceutical companies, and academic partnerships that together move a molecule from the lab to the patient in just a few years, a timeline that would have seemed unthinkable a generation ago.

This funding, often debated during budget discussions in Washington, remains one of the least visible pillars of Western scientific competitiveness, an investment whose returns are measured in lives saved far more than in accounting entries.

International competition that drives progress forward

The speed of this quarter is also explained by increasingly fierce international competition among American, European, and Asian laboratories, each seeking to patent the next molecule capable of transforming the prognosis of a previously hard-to-treat cancer.

This race, far from being purely commercial, directly benefits Western patients, who generally enjoy faster access to innovative treatments than in most other regions of the world, a structural advantage that would be risky to take for granted.

Conclusion: a quarter worth remembering

The overall record of this exceptional period

Between April and June 2026, Western oncology research produced at least fifteen concrete therapeutic advances, covering breast, bladder, and prostate cancer, several blood cancers, and rare cancers like NRG1-fusion cholangiocarcinoma. This pace of innovation, documented in black and white by the AACR, illustrates the continued vitality of Western biomedical research.

Every approval mentioned in this text rests on years of basic research, rigorous clinical trials, and the participation of thousands of volunteer patients, a collective effort that deserves recognition beyond the technical, sometimes unpronounceable drug names alone.

A measured hope to conclude

I close this report with the same caution that has guided my entire argument: these advances are real, documented, and significant, but they do not constitute a definitive victory against cancer. They represent important steps in a fight that will continue to demand research, investment, and patient participation for many years to come.

For patients and their families living with a cancer diagnosis today, this quarterly report should be read as a message of measured hope: science is advancing, concretely, quarter after quarter, even when no one is talking about it on television.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my limits

I am neither an oncologist nor a molecular biology researcher. I am a columnist who translates a technical report published by a recognized scientific organization, the American Association for Cancer Research, into accessible language, trying not to betray its complexity or exaggerate its scope.

I have no clinical expertise allowing me to personally assess the relevance of these treatments for any given patient. This text is an exercise in science communication, not medical advice, and should never replace a consultation with a treating oncologist.

My method for this article

I used as my primary source the detailed quarterly report published by the AACR, which catalogs each approval along with its associated clinical data. No drug name, statistic, or therapeutic indication mentioned in this text was invented or inferred beyond what this document explicitly reports.

The issues of cost and treatment access, as well as the methodological limits of accelerated approvals, were added on my own initiative to temper an enthusiasm that, without them, might have seemed excessive or disconnected from the realities of the health system.

Sources

Primary sources

American Association for Cancer Research — Report on FDA oncology approvals, April-June 2026 — July 2, 2026

FDA — Approval of sacituzumab govitecan as monotherapy and in combination with pembrolizumab

Secondary sources

Gilead — FDA approves Trodelvy for first-line treatment of metastatic triple-negative breast cancer

The Cancer Letter — Analysis of therapeutic targets and oncology drugs — July 2, 2026

Yahoo Finance — The Tigerlily Foundation celebrates an FDA approval

STAT News — Specialized health and oncology coverage